Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis

Brandon L. Jutras,Robert B. Lochhead,Zachary A. Kloos,Jacob Biboy,Klemen Strle,Carmen J. Booth,Sander K. Govers,Joe Gray,Peter Schumann,Waldemar Vollmer,Linda K. Bockenstedt,Allen C. Steere,Christine Jacobs-Wagner
DOI: https://doi.org/10.1073/pnas.1904170116
IF: 11.1
2019-06-17
Proceedings of the National Academy of Sciences
Abstract:Significance Lyme disease, caused by the spirochete Borrelia burgdorferi , is the most common vector-borne disease in North America. If early infection is untreated, it can result in late-stage manifestations, including arthritis. Although antibiotics are generally effective at all stages of the disease, arthritis may persist in some patients for months to several years despite oral and intravenous antibiotic treatment. Excessive, dysregulated host immune responses are thought to play an important role in this outcome, but the underlying mechanisms are not completely understood. This study identifies the B. burgdorferi peptidoglycan, a major component of the cell wall, as an immunogen likely to contribute to inflammation during infection and in cases of postinfectious Lyme arthritis.
multidisciplinary sciences
What problem does this paper attempt to address?